iRadimed (NASDAQ:IRMD - Get Free Report) is expected to be posting its Q3 2026 results before the market opens on Friday, October 30th. Analysts expect the company to announce earnings of $0.55 per share and revenue of $23.47 million for the quarter. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. Interested persons may review the information on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, October 30, 2026 at 11:00 AM ET.
iRadimed (NASDAQ:IRMD - Get Free Report) last posted its quarterly earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.02. The firm had revenue of $20.47 million during the quarter, compared to analysts' expectations of $20.35 million. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.
iRadimed Price Performance
Shares of NASDAQ:IRMD opened at $85.82 on Monday. iRadimed has a 1 year low of $75.75 and a 1 year high of $107.90. The company has a market cap of $1.10 billion, a P/E ratio of 47.94 and a beta of 0.91. The stock's fifty day moving average price is $86.02 and its 200-day moving average price is $90.06.
iRadimed Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 28th. Investors of record on Friday, August 14th were issued a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date was Friday, August 14th. iRadimed's dividend payout ratio (DPR) is presently 44.69%.
Wall Street Analysts Forecast Growth
Several equities analysts have issued reports on the stock. Needham & Company LLC started coverage on shares of iRadimed in a research note on Tuesday, September 22nd. They set a "hold" rating on the stock. Wall Street Zen lowered shares of iRadimed from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, Weiss Ratings upgraded shares of iRadimed from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Friday, October 16th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $120.00.
Check Out Our Latest Report on IRMD
Insider Activity
In related news, Director Monty K. Allen sold 1,419 shares of iRadimed stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $86.41, for a total value of $122,615.79. Following the completion of the sale, the director owned 19,581 shares of the company's stock, valued at $1,691,994.21. The trade was a 6.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 34.60% of the stock is currently owned by company insiders.
iRadimed Company Profile
(
Get Free Report)
iRadimed Corporation NASDAQ: IRMD develops, manufactures and sells medical devices designed for use during magnetic resonance imaging (MRI) procedures. The company focuses on solutions that allow clinicians to deliver intravenous medications and monitor patients safely while they are in or near an MRI scanner.
Its principal products include the MRidium MRI-compatible infusion pump systems, which are designed to administer intravenous fluids and medications without interfering with MRI operations.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider iRadimed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iRadimed wasn't on the list.
While iRadimed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.